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In a variety of observational studies from the population level to 
various clinical situations, it is well known that, a lower heart rate 
is considered to be better.
1) However, in Anglo-Scandinavian Cardiac 
Outcomes Trial study, a vice versa was demonstrated showing an 
inferior protection for stroke by atenolol and bendroflumethiazide 
to amlodipine and perindopril.
2) Despite of several explanations on 
those contradictory findings, findings such as the pharmacodynam-
ics actions, an explanation solely provided by the slow heart rate 
seems to be, at least from a statistical viewpoint, the most powerful.
3) 
In the study by Komukai et al.
4) efonidifine, a dihydropiridine cal-
cium antagonist on the actions of L-type as well as T-type calcium 
channels, showed a significant reduction in the heart rate as well 
as in the blood pressure. It is characterized by rapid onset and du-
rable action which is independent of the administration time. In 
the previous study by Oh et al.
5) efonidipine also showed similar 
efficacy, in regards to, slowing down the heart rate by approxi-
mately 11% in the mild to moderate hypertension patients. Komu-
kai et al.
4) postulated that heart rate reduction could be partially 
explained by slowly fading antihypertensive action, which was de-
monstrated by a non-linear fitting model, based periodic function. 
In essential hypertension, slowing down the heart rate by atenolol 
is rather closely related to the worsening of central hemodynamics. 
Moreover, there is no evidence supporting the hypothesis that the 
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slower heart rate is better, in any direct comparison study. Recently, 
a 12 month follow up study for the patient with diabetic nephropa-
thy done by Sasake et al.
6) showed that efonidipine was better in 
reducing arterial stiffness than amlodipine, through the actions on 
aldosterone, renal function, and oxidative stress. Unfortunately, the 
blood pressure and the heart rate data were not demonstrated well 
enough to detect the difference between the groups.
Putting those altogether, there seems to be a possibility that intrin-
sic pharmakodynamic properties of efonidipine could compensate 
or overcome the potential or relative disadvantage caused by a de-
ceased heart rate on the arterial stiffness. 
Due to ethical issues, a study replacing heart rate slowing drugs 
for beta-blocker in the coronary artery disease is currently not al-
lowed. Therefore, the beta-blocker therapy for coronary artery dis-
ease is not to be replaced by other rate slowing drugs, according to 
the current evidences. Even with a significant reduction in the sec-
ondary composite end points in the MorBidity-mortality EvAIUa-
Tion of the /f inhibitor ivabradine in patients with coronary artery 
disease and left ventricULar dysfunction (BEAUTIFUL) study sub-
group of heart rate of 70 beat per minute or greater, it is needless 
to say that the efficacy of ivabradine is not to be extrapolated to 
the essential hypertension patients.
7) But at the same time, at least, 
ivabradine data did suggest that the harmful effects, demonstrated 
by atenolol, might not be universal to all the beta-blockers.
7) 
Mechanism of action of efonidipine on the sinus node is quite si-
milar to that of ivabradine.
8) Considering potential efficacy on the 
arterial stiffness, the “BEAUTIFUL-like action” in addition to modest 
antihypertensive efficacy, provided by efonidipine, is something “th-
robbing”. Especially studies for central hemodynamics and a direct 
comparison study would be very interesting.
Another interesting hypothesis, regarding efonidipine, is that the 
dissociation of the durability on blood pressure and the heart rate 
could be an alternative to the trade-off between potent blood pres-
sure lowering and the reflex tachycardia common in other dihydro-
phyridine calcium antagonists. Since the 24 hours blood pressure 
reduction is partly contributed by nocturnal blood pressure reduc-230  Efonidipine, Another Beauty Relieving the Pressure
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tion, modest efonidipine efficacy on nocturnal blood pressure 
needs to be considered for individualized patient care. 
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